NOVAVAX INC 8K

Novavax, Inc. announced substantially lower second-quarter 2026 revenue and a net loss, updated its 2026 financial guidance, and highlighted progress and milestone potential under its Sanofi partnership and internal vaccine pipeline.

On August 6, 2026, Novavax, Inc. reported its financial results for the quarter ended June 30, 2026, disclosing total revenue of $57 million (down 76% year over year) driven by higher Matrix-M product demand but the absence of large prior-year milestones, a net loss of $53 million versus prior-year net income of $107 million, cash and investments of $724 million, and updates to its 2026 financial outlook, including lowered combined R&D and SG&A expense guidance and a raised Adjusted Total Revenue framework to $235–$275 million, while also providing operational updates on its Sanofi partnership, including anticipated milestone-triggering events for a Phase 3 COVID-19-Influenza Combination trial and manufacturing technology transfer, as well as progress on Matrix-M collaborations and its C. difficile vaccine program.

Filing Facts

CIK

1000694

Ticker

NVAX

Form

8K

Source Type

fda

Accession

0001000694-26-000019

Alert Tier

6